CAMBRIDGE, Ma. — Moderna has no plans to share the recipe for its COVID-19 vaccine because executives have concluded that scaling up the company’s own production is the best way to increase the global supply, the company’s chairman Noubar Afeyan said in an interview with the Associated Press.
Afeyan also reiterated a pledge Moderna made a year ago not to enforce patent infringement on anyone else making a coronavirus vaccine during the pandemic. “We didn’t have to do that,” Afeyan said. ”We think that was the right, responsible thing to do.” He added: “We want that to be helping the world.”
The United Nations health agency has pressed Moderna to share its vaccine formula. Afeyan said the company analyzed whether it would be better to share the messenger RNA technology and determined that it could expand production and deliver billions of additional doses in 2022.
“Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them,” Afeyan said. Asked about appeals from the World Health Organization and others, he contended that such pleas assumed ”that we couldn’t get enough capacity, but in fact we know we can.”
Moderna “went from having zero production to having 1 billion doses in less than a year,” Afeyan said, referring to the Massachusetts-based company’s sprint to develop the vaccine and produce it in large quantities. “And we think we will be able to go from 1 to 3 billion” in 2022. “We think we are doing everything we can to help this pandemic,” Afeyan added, citing the company’s increasing output and its pledge on patent infringement.
He noted that $2.5 billion (about 2.1 billion euros) and 10 years were spent in developing the platform that makes Moderna’s COVID-19 vaccine. “Others joined the hunt when COVID-19 came along, and we’re glad to see that the capacity therefore has been increased considerably beyond what Moderna would have been able to do” by itself, Afeyan said.